We may earn a commission for purchases through links on our site at no cost to you, Learn more. All trademarks and brand names are the property of their respective owners. All Wegovy product and service names used in this website are for informational purposes only. Use of these names and brands does not imply endorsement.
- Wegovy (semaglutide) demonstrated sustained weight loss of 10.2% on average over four years in the SELECT trial, the longest study of the drug to date.
- Participants typically lost weight for about 65 weeks before reaching a plateau.
- 68% of those on the highest dose of Wegovy lost at least 5% of their body weight, compared to 21% on placebo.
- The study suggests Wegovy’s benefits may extend beyond weight loss, potentially involving improved blood glucose control or reduced inflammation.
- The drug’s high cost (about $1,349 for a one-month supply) remains a barrier for many patients, even with insurance.
- The drug showed cardiovascular benefits independent of weight loss, reducing the risk of heart attack, stroke, and cardiovascular-related death.
- Questions remain about whether non-obese individuals with cardiovascular risks could benefit from Wegovy.
- The findings may prompt insurers to reevaluate criteria for reimbursing these medications, given their significant cardiovascular benefits.
According to clinical trials conducted by Novo Nordisk, adults taking Wegovy lost an average of 15% of their body weight (about 35 pounds) after one year of treatment, compared to a 2.5% weight loss in those taking a placebo.
Comparing Wegovy to other weight loss medications
Wegovy has shown superior weight loss results compared to other medications. In clinical trials, Wegovy users lost an average of 15% of their body weight over 68 weeks, while those taking Saxenda (liraglutide) lost about 7% on average.
Ozempic, which contains a lower dose of semaglutide, led to approximately 7% weight loss in people with diabetes over the same period. Other options like Qsymia, Saxenda, and Adipex-P may be effective but generally produce less weight loss than Wegovy.
However, individual results can vary, and factors like side effects, cost, and insurance coverage should be considered when choosing a medication. It’s important to note that these drugs are typically prescribed for obesity or overweight individuals with related health conditions, not for cosmetic weight loss in those at a healthy weight.
Long-term weight maintenance with Wegovy
Recent long-term studies have demonstrated the efficacy of Wegovy (semaglutide) in maintaining weight loss over extended periods.
A clinical trial involving over 17,000 participants found that patients taking Wegovy maintained an average weight loss of 10.2% for up to four years. This sustained weight loss was achieved without structured diet and exercise interventions, suggesting the drug’s potential for long-term obesity management.
However, it’s important to note that obesity is considered a chronic condition, and discontinuation of the medication often leads to weight regain. Approximately 17% of patients in the four-year study withdrew due to side effects, primarily gastrointestinal issues.
These findings underscore the importance of viewing obesity treatment as an ongoing process, similar to managing other chronic diseases like diabetes or hypertension.
Factors influencing weight loss on Wegovy
Several factors can influence the effectiveness of Wegovy for weight loss. While the medication is a powerful tool, optimal results are typically achieved with lifestyle modifications.
A balanced diet and increased physical activity are crucial for maximizing weight loss outcomes. Additionally, psychological factors play a role in the success of weight loss efforts with Wegovy. Individual responses to the medication may vary based on factors such as starting weight, metabolism, and adherence to the prescribed regimen.
It’s important to note that Wegovy is specifically approved for individuals with a BMI of 30 or greater (obese) or those with a BMI of 27 or greater (overweight) who have at least one weight-related comorbidity.
Other health conditions, medications, and genetic factors can also influence the effectiveness of Wegovy. Patients should work closely with their healthcare providers to monitor progress and adjust treatment plans as needed for optimal results.